The Institut Pasteur, a Carnot institute since 2007, and the start-up studio Argobio announced in February 2025 the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections. The platform leverages state-of-the-art generative artificial intelligence (AI) to design selective inhibitors Sec61/ translocon molecular complex for blocking and degrading pathogenic proteins. Enodia Therapeutics is the winner of Pfizer sponsor BioLabs Hôtel-Dieu coveted 2025 Golden Ticket competition.
The start-up Enodia Therapeutics stems from pioneering research at the Institut Pasteur, with the discovery of the mechanism of action of Mycolactone, a natural Sec61 inhibitor responsible for Buruli Ulcers. “Our infectious diseases research revealed a new way to target disease-causing proteins. This breakthrough highlights how fundamental research can help uncover entirely new therapeutic opportunities” said Pr. Caroline Demangel, co-founder of Enodia Therapeutics and Head of the Immunobiology and Therapy Unit at the Institut Pasteur.
The initial scientific project was supported by the Institut Pasteur Innovation Accelerator. This program supports projects based on laboratory discoveries with strong commercial potential. The Innovation Accelerator enables complementary scientific developments necessary for technology transfer.
With the creation of its first spin-off company in 1997, the Institut Pasteur has been a pioneer in the creation of spin-off companies based on its research. To date the Institut Pasteur has been involved in the development of 38 spin-off companies.
Enodia Therapeutics was incubated by Argobio, a premier French biotech start-up studio, dedicated to fostering innovative science and accelerating its transition into a fully-fledged biotech company.
For more information, please visit
